deltatrials

Non-small cell lung cancer Trials in Petah Tikva, Israel

Conditions / Non-small cell lung cancer / Petah Tikva, Israel

Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.

30 total trials for this combination

Showing top 10 of 30 trials

Trials

NCT ID Title Status Phase
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) RECRUITING
NCT05538130 A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors RECRUITING
NCT05029882 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab ACTIVE_NOT_RECRUITING PHASE1
NCT00409188 Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) COMPLETED PHASE3
NCT02477826 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) COMPLETED PHASE3
NCT01168973 A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy COMPLETED PHASE3
NCT02152631 A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT00418886 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients COMPLETED PHASE3
NCT06422143 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] RECRUITING
NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING PHASE2

Related Pages